Overview

A Study of a Personalized Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer

Status:
Not yet recruiting

Trial end date:
2027-03-01

Target enrollment:

Participant gender:

Summary

The primary objective of the Phase 2 portion of the study is to characterize the clinical activity of maintenance therapy with GRT-C901/GRT-R902 in combination with checkpoint inhibitors in addition to fluoropyrimidine/bevacizumab versus fluoropyrimidine/bevacizumab alone as assessed by changes in circulating tumor (ct)DNA. The primary objective of the Phase 3 portion is to demonstrate clinical efficacy of the regime as assessed by progression-free survival.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Gritstone Oncology, Inc.

Treatments:

Atezolizumab
Bevacizumab
Ipilimumab
Oxaliplatin